Concepts (315)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Substance-Related Disorders | 49 | 2025 | 740 | 9.870 |
Why?
|
| Mental Disorders | 38 | 2025 | 795 | 9.110 |
Why?
|
| Veterans | 48 | 2025 | 763 | 8.810 |
Why?
|
| Criminals | 10 | 2024 | 60 | 4.100 |
Why?
|
| Recidivism | 8 | 2025 | 30 | 3.740 |
Why?
|
| Opioid-Related Disorders | 23 | 2025 | 513 | 3.460 |
Why?
|
| Cocaine-Related Disorders | 19 | 2017 | 82 | 3.210 |
Why?
|
| Mental Health Services | 16 | 2022 | 288 | 2.470 |
Why?
|
| Residential Treatment | 7 | 2025 | 34 | 2.240 |
Why?
|
| United States Department of Veterans Affairs | 28 | 2025 | 541 | 1.980 |
Why?
|
| Social Stigma | 4 | 2017 | 73 | 1.960 |
Why?
|
| Housing | 9 | 2024 | 73 | 1.870 |
Why?
|
| Criminal Law | 8 | 2025 | 82 | 1.840 |
Why?
|
| Mental Health | 13 | 2023 | 371 | 1.620 |
Why?
|
| Adult | 70 | 2025 | 16906 | 1.590 |
Why?
|
| Schizophrenia | 13 | 2009 | 263 | 1.570 |
Why?
|
| Humans | 128 | 2025 | 63545 | 1.550 |
Why?
|
| Cocaine | 15 | 2017 | 101 | 1.500 |
Why?
|
| Behavior, Addictive | 6 | 2016 | 74 | 1.480 |
Why?
|
| United States | 41 | 2025 | 7839 | 1.440 |
Why?
|
| Pilot Projects | 16 | 2025 | 1015 | 1.400 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 12 | 2025 | 87 | 1.390 |
Why?
|
| Male | 69 | 2025 | 29943 | 1.280 |
Why?
|
| Antipsychotic Agents | 11 | 2009 | 301 | 1.280 |
Why?
|
| Coercion | 2 | 2022 | 60 | 1.260 |
Why?
|
| Substance Withdrawal Syndrome | 13 | 2005 | 123 | 1.240 |
Why?
|
| Evidence-Based Practice | 3 | 2017 | 84 | 1.110 |
Why?
|
| Community Mental Health Services | 3 | 2019 | 94 | 1.100 |
Why?
|
| Female | 61 | 2025 | 32949 | 1.090 |
Why?
|
| Peer Group | 6 | 2020 | 104 | 1.040 |
Why?
|
| Behavior Therapy | 3 | 2025 | 167 | 1.040 |
Why?
|
| Middle Aged | 48 | 2025 | 17662 | 1.020 |
Why?
|
| Program Evaluation | 3 | 2019 | 487 | 1.020 |
Why?
|
| Analgesics, Opioid | 8 | 2024 | 537 | 1.010 |
Why?
|
| Morals | 5 | 2022 | 22 | 1.000 |
Why?
|
| Mentoring | 2 | 2022 | 51 | 0.920 |
Why?
|
| Minority Groups | 2 | 2025 | 141 | 0.880 |
Why?
|
| Risperidone | 6 | 2006 | 25 | 0.880 |
Why?
|
| Cues | 9 | 2017 | 75 | 0.810 |
Why?
|
| Opiate Substitution Treatment | 8 | 2024 | 208 | 0.810 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2023 | 398 | 0.780 |
Why?
|
| Patient Selection | 1 | 2025 | 487 | 0.780 |
Why?
|
| Chronic Pain | 1 | 2025 | 154 | 0.770 |
Why?
|
| Biomedical Research | 1 | 2025 | 269 | 0.760 |
Why?
|
| Comorbidity | 10 | 2025 | 1114 | 0.750 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 436 | 0.750 |
Why?
|
| Case Management | 3 | 2020 | 55 | 0.730 |
Why?
|
| Benzodiazepines | 4 | 2018 | 100 | 0.690 |
Why?
|
| Prisons | 3 | 2019 | 112 | 0.660 |
Why?
|
| Drug Overdose | 2 | 2021 | 131 | 0.650 |
Why?
|
| Schizophrenic Psychology | 5 | 2009 | 66 | 0.650 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 123 | 0.630 |
Why?
|
| Social Support | 2 | 2019 | 373 | 0.620 |
Why?
|
| Tobacco Use Disorder | 6 | 2023 | 245 | 0.620 |
Why?
|
| Electroretinography | 9 | 2001 | 26 | 0.620 |
Why?
|
| Social Perception | 1 | 2019 | 41 | 0.610 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2019 | 14 | 0.600 |
Why?
|
| Psychiatry | 1 | 2021 | 126 | 0.600 |
Why?
|
| Task Performance and Analysis | 2 | 2018 | 129 | 0.580 |
Why?
|
| Pharmacies | 1 | 2018 | 36 | 0.570 |
Why?
|
| Treatment Outcome | 13 | 2025 | 5628 | 0.560 |
Why?
|
| Educational Technology | 1 | 2018 | 9 | 0.560 |
Why?
|
| Craving | 5 | 2024 | 36 | 0.560 |
Why?
|
| Recovery of Function | 1 | 2019 | 286 | 0.540 |
Why?
|
| Crime | 1 | 2018 | 57 | 0.530 |
Why?
|
| Computer-Assisted Instruction | 1 | 2018 | 80 | 0.530 |
Why?
|
| Attitude to Health | 1 | 2019 | 293 | 0.520 |
Why?
|
| Massachusetts | 8 | 2022 | 2072 | 0.510 |
Why?
|
| Buprenorphine | 5 | 2023 | 194 | 0.500 |
Why?
|
| Cell Phone | 2 | 2014 | 43 | 0.500 |
Why?
|
| Informed Consent | 1 | 2017 | 140 | 0.500 |
Why?
|
| Learning | 1 | 2018 | 182 | 0.490 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2025 | 776 | 0.490 |
Why?
|
| Research | 1 | 2016 | 195 | 0.460 |
Why?
|
| Autism Spectrum Disorder | 1 | 2018 | 179 | 0.440 |
Why?
|
| Smoking Cessation | 5 | 2023 | 548 | 0.430 |
Why?
|
| Algorithms | 3 | 2020 | 1004 | 0.420 |
Why?
|
| Cognition Disorders | 3 | 2015 | 217 | 0.410 |
Why?
|
| Wearable Electronic Devices | 3 | 2024 | 69 | 0.400 |
Why?
|
| Internet | 2 | 2014 | 468 | 0.400 |
Why?
|
| Neuropsychological Tests | 6 | 2003 | 393 | 0.390 |
Why?
|
| Receptors, Opioid, mu | 1 | 2012 | 13 | 0.380 |
Why?
|
| Breathing Exercises | 1 | 2012 | 5 | 0.380 |
Why?
|
| Receptors, GABA-A | 1 | 2012 | 24 | 0.380 |
Why?
|
| Primary Health Care | 2 | 2017 | 697 | 0.370 |
Why?
|
| Counseling | 5 | 2023 | 368 | 0.370 |
Why?
|
| Synaptic Transmission | 1 | 2012 | 149 | 0.350 |
Why?
|
| Prisoners | 3 | 2019 | 166 | 0.340 |
Why?
|
| Psychiatric Status Rating Scales | 8 | 2009 | 390 | 0.340 |
Why?
|
| Psychotherapy, Brief | 1 | 2010 | 17 | 0.330 |
Why?
|
| Telemedicine | 2 | 2014 | 331 | 0.320 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 491 | 0.320 |
Why?
|
| Alcoholism | 5 | 2021 | 318 | 0.310 |
Why?
|
| Health Services Accessibility | 6 | 2021 | 566 | 0.310 |
Why?
|
| Attitude of Health Personnel | 3 | 2024 | 604 | 0.290 |
Why?
|
| Cluster Analysis | 3 | 2019 | 263 | 0.280 |
Why?
|
| Neural Pathways | 1 | 2008 | 99 | 0.280 |
Why?
|
| Stress, Psychological | 2 | 2024 | 474 | 0.280 |
Why?
|
| Young Adult | 9 | 2024 | 4720 | 0.270 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 159 | 0.260 |
Why?
|
| Qualitative Research | 6 | 2024 | 707 | 0.260 |
Why?
|
| Telephone | 3 | 2023 | 122 | 0.260 |
Why?
|
| Depression | 2 | 2012 | 908 | 0.260 |
Why?
|
| Stereotyping | 2 | 2016 | 19 | 0.260 |
Why?
|
| Social Discrimination | 2 | 2016 | 13 | 0.260 |
Why?
|
| Veterans Health | 5 | 2021 | 157 | 0.250 |
Why?
|
| Feasibility Studies | 3 | 2021 | 570 | 0.250 |
Why?
|
| Psychotherapy | 2 | 2017 | 99 | 0.250 |
Why?
|
| Prejudice | 2 | 2016 | 62 | 0.250 |
Why?
|
| Monitoring, Ambulatory | 3 | 2015 | 57 | 0.240 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 88 | 0.230 |
Why?
|
| Substance Abuse Detection | 2 | 2015 | 45 | 0.230 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 2025 | 119 | 0.220 |
Why?
|
| Acute Pain | 1 | 2024 | 21 | 0.220 |
Why?
|
| Dopamine Antagonists | 1 | 2004 | 16 | 0.220 |
Why?
|
| Serotonin Antagonists | 1 | 2004 | 32 | 0.220 |
Why?
|
| Sleep Wake Disorders | 1 | 2025 | 73 | 0.220 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2025 | 156 | 0.210 |
Why?
|
| Health Status | 3 | 2020 | 443 | 0.210 |
Why?
|
| Smoking Prevention | 2 | 2015 | 162 | 0.200 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 2592 | 0.200 |
Why?
|
| Retinal Cone Photoreceptor Cells | 4 | 1997 | 27 | 0.200 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2002 | 8 | 0.200 |
Why?
|
| World Health Organization | 1 | 2022 | 34 | 0.190 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 486 | 0.190 |
Why?
|
| Epidemics | 1 | 2022 | 25 | 0.180 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2017 | 25 | 0.180 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 2463 | 0.180 |
Why?
|
| Cannabidiol | 1 | 2020 | 6 | 0.170 |
Why?
|
| Health Planning | 1 | 2021 | 32 | 0.170 |
Why?
|
| Social Problems | 1 | 2020 | 5 | 0.170 |
Why?
|
| Health Personnel | 1 | 2024 | 377 | 0.170 |
Why?
|
| Outpatients | 2 | 2012 | 138 | 0.170 |
Why?
|
| Interview, Psychological | 2 | 2017 | 79 | 0.170 |
Why?
|
| Severity of Illness Index | 4 | 2019 | 1553 | 0.160 |
Why?
|
| Public Housing | 1 | 2020 | 13 | 0.160 |
Why?
|
| Employment | 1 | 2021 | 128 | 0.160 |
Why?
|
| Patient Compliance | 3 | 2013 | 360 | 0.160 |
Why?
|
| Vaping | 1 | 2020 | 43 | 0.160 |
Why?
|
| Quality of Life | 3 | 2025 | 1241 | 0.160 |
Why?
|
| Aged | 12 | 2021 | 14454 | 0.150 |
Why?
|
| Sex Factors | 3 | 2018 | 973 | 0.150 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2020 | 71 | 0.150 |
Why?
|
| Health Plan Implementation | 2 | 2017 | 40 | 0.150 |
Why?
|
| Public Opinion | 1 | 2019 | 25 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2018 | 784 | 0.150 |
Why?
|
| Gambling | 2 | 2016 | 18 | 0.150 |
Why?
|
| Diabetes Mellitus | 3 | 2009 | 541 | 0.150 |
Why?
|
| Methadone | 4 | 2023 | 135 | 0.150 |
Why?
|
| Double-Blind Method | 5 | 2015 | 738 | 0.140 |
Why?
|
| Community Health Centers | 1 | 2019 | 92 | 0.140 |
Why?
|
| Tobacco Use | 1 | 2018 | 39 | 0.140 |
Why?
|
| Retinal Rod Photoreceptor Cells | 1 | 1998 | 21 | 0.140 |
Why?
|
| Recurrence | 4 | 2015 | 640 | 0.140 |
Why?
|
| Boston | 1 | 2019 | 250 | 0.140 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 211 | 0.140 |
Why?
|
| Program Development | 1 | 2019 | 207 | 0.140 |
Why?
|
| Color Vision Defects | 1 | 1997 | 1 | 0.140 |
Why?
|
| Psychology, Clinical | 1 | 1997 | 7 | 0.140 |
Why?
|
| Alcohol Drinking | 2 | 2021 | 315 | 0.130 |
Why?
|
| Perception | 1 | 2018 | 175 | 0.130 |
Why?
|
| Dopamine | 3 | 2008 | 107 | 0.130 |
Why?
|
| Los Angeles | 1 | 2017 | 13 | 0.130 |
Why?
|
| Evidence-Based Medicine | 2 | 2018 | 460 | 0.130 |
Why?
|
| Needs Assessment | 2 | 2024 | 202 | 0.130 |
Why?
|
| Legislation, Medical | 1 | 2017 | 4 | 0.130 |
Why?
|
| Thinking | 1 | 2017 | 29 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2018 | 219 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2018 | 134 | 0.130 |
Why?
|
| Logistic Models | 3 | 2020 | 1267 | 0.130 |
Why?
|
| Pandemics | 1 | 2022 | 674 | 0.130 |
Why?
|
| Culture | 1 | 2017 | 80 | 0.130 |
Why?
|
| Risk Factors | 3 | 2019 | 5282 | 0.130 |
Why?
|
| Anxiety Disorders | 1 | 2017 | 192 | 0.120 |
Why?
|
| Cooperative Behavior | 2 | 2024 | 223 | 0.120 |
Why?
|
| Adolescent | 7 | 2021 | 6263 | 0.120 |
Why?
|
| Social Justice | 1 | 2016 | 33 | 0.120 |
Why?
|
| Buprenorphine, Naloxone Drug Combination | 1 | 2015 | 26 | 0.120 |
Why?
|
| Memantine | 1 | 2015 | 23 | 0.120 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 333 | 0.120 |
Why?
|
| Age Factors | 2 | 2018 | 1561 | 0.120 |
Why?
|
| Naloxone | 1 | 2015 | 61 | 0.110 |
Why?
|
| Haloperidol | 2 | 2006 | 16 | 0.110 |
Why?
|
| Risk-Taking | 1 | 2016 | 162 | 0.110 |
Why?
|
| Depressive Disorder | 1 | 2017 | 286 | 0.110 |
Why?
|
| Bipolar Disorder | 2 | 2009 | 246 | 0.110 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 137 | 0.110 |
Why?
|
| Appointments and Schedules | 1 | 2014 | 60 | 0.100 |
Why?
|
| Hospitalization | 2 | 2018 | 1359 | 0.100 |
Why?
|
| Reminder Systems | 1 | 2014 | 75 | 0.100 |
Why?
|
| Biosensing Techniques | 1 | 2015 | 119 | 0.100 |
Why?
|
| Surveys and Questionnaires | 5 | 2013 | 2703 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2022 | 3293 | 0.100 |
Why?
|
| Cognition | 3 | 2023 | 484 | 0.100 |
Why?
|
| Health Behavior | 1 | 2016 | 473 | 0.100 |
Why?
|
| Clinical Competence | 1 | 1997 | 725 | 0.090 |
Why?
|
| Women's Health | 1 | 2015 | 371 | 0.090 |
Why?
|
| Adolescent Behavior | 1 | 1993 | 194 | 0.090 |
Why?
|
| Child | 2 | 2020 | 4541 | 0.090 |
Why?
|
| Skin | 1 | 2015 | 375 | 0.090 |
Why?
|
| Research Design | 1 | 2015 | 576 | 0.090 |
Why?
|
| Training Support | 1 | 2012 | 22 | 0.090 |
Why?
|
| Motivation | 3 | 2015 | 289 | 0.090 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 5468 | 0.090 |
Why?
|
| Biomarkers | 2 | 2024 | 1405 | 0.090 |
Why?
|
| Patient Care Team | 2 | 2013 | 340 | 0.080 |
Why?
|
| Educational Status | 1 | 2012 | 278 | 0.080 |
Why?
|
| Machine Learning | 2 | 2024 | 181 | 0.080 |
Why?
|
| Genotype | 1 | 2012 | 664 | 0.080 |
Why?
|
| Psychometrics | 3 | 2005 | 384 | 0.080 |
Why?
|
| Affect | 3 | 2017 | 127 | 0.080 |
Why?
|
| Interdisciplinary Communication | 1 | 2009 | 106 | 0.070 |
Why?
|
| Anti-HIV Agents | 1 | 2010 | 154 | 0.070 |
Why?
|
| Pharmacists | 1 | 2009 | 127 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2009 | 204 | 0.070 |
Why?
|
| Psychotic Disorders | 1 | 2009 | 158 | 0.070 |
Why?
|
| Color Perception | 2 | 1997 | 4 | 0.070 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6620 | 0.070 |
Why?
|
| Patient Dropouts | 1 | 2006 | 49 | 0.060 |
Why?
|
| Treatment Refusal | 1 | 2006 | 56 | 0.060 |
Why?
|
| Naltrexone | 2 | 2018 | 89 | 0.060 |
Why?
|
| New Jersey | 2 | 2004 | 26 | 0.060 |
Why?
|
| Time Factors | 3 | 2015 | 3708 | 0.060 |
Why?
|
| Interviews as Topic | 2 | 2018 | 531 | 0.060 |
Why?
|
| Self Report | 2 | 2020 | 382 | 0.060 |
Why?
|
| Galvanic Skin Response | 2 | 2015 | 24 | 0.060 |
Why?
|
| Smoking | 2 | 2016 | 863 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2015 | 1664 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 458 | 0.050 |
Why?
|
| Pirenzepine | 1 | 2003 | 5 | 0.050 |
Why?
|
| Ambulatory Care | 2 | 2023 | 311 | 0.050 |
Why?
|
| Mental Processes | 1 | 2023 | 18 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 605 | 0.050 |
Why?
|
| HIV Infections | 1 | 2010 | 972 | 0.050 |
Why?
|
| England | 1 | 2022 | 30 | 0.050 |
Why?
|
| Longitudinal Studies | 2 | 2024 | 1260 | 0.050 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2002 | 119 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 136 | 0.050 |
Why?
|
| Secondary Prevention | 1 | 2023 | 164 | 0.050 |
Why?
|
| Problem Solving | 1 | 2002 | 32 | 0.050 |
Why?
|
| Reaction Time | 1 | 2002 | 125 | 0.040 |
Why?
|
| Universities | 1 | 2022 | 162 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2005 | 519 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2002 | 374 | 0.040 |
Why?
|
| Psychomotor Performance | 1 | 2002 | 136 | 0.040 |
Why?
|
| Dronabinol | 1 | 2020 | 32 | 0.040 |
Why?
|
| Attention | 1 | 2002 | 147 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 19 | 0.040 |
Why?
|
| Social Welfare | 1 | 2020 | 23 | 0.040 |
Why?
|
| Nicotine | 1 | 2020 | 116 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2015 | 435 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 75 | 0.040 |
Why?
|
| Chlorpromazine | 1 | 1999 | 8 | 0.040 |
Why?
|
| Mindfulness | 1 | 2020 | 70 | 0.040 |
Why?
|
| Clozapine | 1 | 1999 | 32 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 1383 | 0.040 |
Why?
|
| Heart Rate | 1 | 2020 | 321 | 0.040 |
Why?
|
| Drive | 1 | 1997 | 2 | 0.030 |
Why?
|
| Communication | 1 | 2023 | 581 | 0.030 |
Why?
|
| Eye Movement Measurements | 1 | 2017 | 20 | 0.030 |
Why?
|
| Color Perception Tests | 1 | 1997 | 1 | 0.030 |
Why?
|
| Psychological Tests | 1 | 2017 | 46 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 847 | 0.030 |
Why?
|
| Pennsylvania | 1 | 2017 | 64 | 0.030 |
Why?
|
| Psychological Theory | 1 | 1997 | 26 | 0.030 |
Why?
|
| Education, Graduate | 1 | 1997 | 17 | 0.030 |
Why?
|
| Executive Function | 1 | 2017 | 65 | 0.030 |
Why?
|
| Attitude | 1 | 2017 | 102 | 0.030 |
Why?
|
| Eye Movements | 1 | 2017 | 83 | 0.030 |
Why?
|
| Research Personnel | 1 | 1997 | 94 | 0.030 |
Why?
|
| Retina | 1 | 1997 | 124 | 0.030 |
Why?
|
| Forecasting | 1 | 1997 | 233 | 0.030 |
Why?
|
| Teaching | 1 | 1997 | 161 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2020 | 503 | 0.030 |
Why?
|
| Skin Temperature | 1 | 2015 | 19 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2002 | 2571 | 0.030 |
Why?
|
| Substance Abuse Treatment Centers | 2 | 2010 | 104 | 0.030 |
Why?
|
| Motion | 1 | 2015 | 59 | 0.030 |
Why?
|
| Interpersonal Relations | 1 | 2016 | 152 | 0.030 |
Why?
|
| Body Temperature | 1 | 2015 | 45 | 0.030 |
Why?
|
| Chronic Disease | 2 | 2009 | 751 | 0.030 |
Why?
|
| Wrist | 1 | 2015 | 39 | 0.030 |
Why?
|
| Motor Activity | 1 | 2017 | 346 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2018 | 443 | 0.030 |
Why?
|
| Medicare | 2 | 2009 | 612 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 866 | 0.030 |
Why?
|
| Primary Prevention | 1 | 1993 | 137 | 0.020 |
Why?
|
| Health Education | 1 | 1993 | 190 | 0.020 |
Why?
|
| Wireless Technology | 1 | 2012 | 18 | 0.020 |
Why?
|
| Vocational Guidance | 1 | 2012 | 19 | 0.020 |
Why?
|
| Mass Screening | 1 | 1996 | 692 | 0.020 |
Why?
|
| Focus Groups | 1 | 2012 | 305 | 0.020 |
Why?
|
| Health Services Research | 1 | 2012 | 270 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2010 | 94 | 0.020 |
Why?
|
| Drug Packaging | 1 | 2009 | 11 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2009 | 177 | 0.020 |
Why?
|
| Obesity | 1 | 2016 | 1234 | 0.020 |
Why?
|
| Population | 1 | 2007 | 13 | 0.020 |
Why?
|
| Classification | 1 | 2007 | 12 | 0.020 |
Why?
|
| Personality Inventory | 1 | 2005 | 56 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2005 | 146 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 127 | 0.010 |
Why?
|
| Benztropine | 1 | 2003 | 2 | 0.010 |
Why?
|
| Akathisia, Drug-Induced | 1 | 2003 | 5 | 0.010 |
Why?
|
| Muscarinic Antagonists | 1 | 2003 | 33 | 0.010 |
Why?
|
| Health Services | 1 | 2003 | 82 | 0.010 |
Why?
|
| Health Care Costs | 1 | 2003 | 215 | 0.010 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 1999 | 1 | 0.010 |
Why?
|
| Agranulocytosis | 1 | 1999 | 6 | 0.010 |
Why?
|
| Color | 1 | 1997 | 25 | 0.010 |
Why?
|
| Weight Gain | 1 | 1999 | 168 | 0.010 |
Why?
|
| Arousal | 1 | 1996 | 42 | 0.010 |
Why?
|
| Reference Values | 1 | 1996 | 332 | 0.010 |
Why?
|
| Patient Admission | 1 | 1996 | 198 | 0.010 |
Why?
|
| Incidence | 1 | 1996 | 1372 | 0.010 |
Why?
|